Agency Information Collection Activities; Proposed Collection; Comment Request; Tobacco Health Document Submission, 42664-42666 [2018-18212]
Download as PDF
42664
Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices
II. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information that are subject to review by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in 21 CFR
parts 312 and 314 have been approved
under OMB control numbers 0910–0014
and 0910–0001, respectively.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/default.htm, https://
www.fda.gov/MedicalDevices/Device
RegulationandGuidance/
GuidanceDocuments/default.htm, or
https://www.regulations.gov.
Dated: August 20, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–18214 Filed 8–22–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0377]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Tobacco Health
Document Submission
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on Tobacco Health
Document Submissions.
DATES: Submit either electronic or
written comments on the collection of
information by October 22, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:43 Aug 22, 2018
Jkt 244001
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before October 22,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of October 22, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–0377 for ‘‘Tobacco Health
Document Submission.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
E:\FR\FM\23AUN1.SGM
23AUN1
Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
daltland on DSKBBV9HB2PROD with NOTICES
Tobacco Health Document Submission
OMB Control Number 0910–0654—
Extension
On June 22, 2009, the President
signed the Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111–31) into law.
The Tobacco Control Act amended the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) by adding, among other
things, a new chapter granting FDA
important authority to regulate the
manufacture, marketing, and
distribution of tobacco products to
protect the public health generally and
to reduce tobacco use by minors.
Additionally, section 101 of the Tobacco
Control Act amended the FD&C Act by
adding, among other things, new section
904(a)(4) (21 U.S.C. 387d(a)(4)).
Section 904(a)(4) of the FD&C Act
requires each tobacco product
manufacturer or importer, or agent
thereof, to submit all documents
developed after June 22, 2009, ‘‘that
relate to health, toxicological,
behavioral, or physiologic effects of
current or future tobacco products, their
constituents (including smoke
constituents), ingredients, components,
and additives’’ (herein referred to as
‘‘tobacco health documents’’).
VerDate Sep<11>2014
19:43 Aug 22, 2018
Jkt 244001
FDA announced the availability of a
guidance on this collection in the
Federal Register of April 4, 2010 (75 FR
20606) (revised December 5, 2016 (81
FR 87565) and August 10, 2017 (82 FR
37459) (extending compliance dates)),
and requested health documents that
were created during the period of June
23, 2009, through December 31, 2009
based on the statutory requirements.
The guidance stated that information
required under section 904(a)(4) of the
FD&C Act must be submitted to FDA
beginning December 22, 2009. However,
FDA also explained that it did not
intend to enforce the December 22,
2009, deadline provided that the
documents were submitted by April 30,
2010, for all health documents
developed between June 23, 2009 and
December 31, 2009. Further, FDA stated
it would publish a revised guidance
specifying the timing of subsequent
reporting.
FDA has been collecting the
information submitted pursuant to
section 904(a)(4) of the FD&C Act
through a facilitative electronic form
and through a paper form (Form FDA
3743) for those individuals who choose
not to use the electronic method. On
both forms, FDA is requesting the
following information from firms that
have not already reported or still have
documents to report:
• Submitter identification
• Submitter type, company name,
address, country, company
headquarters Dun and Bradstreet
D–U–N–S number, and FDA assigned
Facility Establishment Identifier (FEI)
number
• Submitter point of contact
• Contact name, title, position title,
email, telephone, and fax
• Submission format and contents (as
applicable)
• Electronic documents: Media type,
media quantity, size of submission,
quantity of documents, file type, and
file software
• Paper documents: Quantity of
documents, quantity of volumes, and
quantity of boxes
• Whether or not a submission is being
provided
• Confirmation statement
• Identification and signature of
submitter including name, company
name, address, position title, email,
telephone, and fax
• Document categorization (as
applicable): Relationship of the
document or set of documents to the
following:
Æ Health, behavioral, toxicological, or
physiological effects
Æ Uniquely identified current or future
tobacco product(s)
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
42665
Æ Category of current or future tobacco
product(s)
Æ Specific ingredient(s), constituent(s),
component(s), or additive(s)
Æ Class of ingredient(s), constituent(s),
component(s), or additive(s)
• Document readability and
accessibility: Keywords; glossary or
explanation of any abbreviations, jargon,
or internal (e.g., code) names; special
instructions for loading or compiling
submission.
• Document metadata: Date document
was created, document author(s),
document recipient(s), document
custodian, document title or
identification number, beginning and
ending Bates numbers, Bates number
ranges for documents attached to a
submitted email, document type, and
whether the document is present in the
University of California San Francisco’s
Truth Tobacco Documents database.
In addition to the electronic and
paper forms, FDA issued guidance
documents intended to assist persons
making tobacco health document
submissions (draft guidance: December
28, 2009 (74 FR 68629); final guidance:
April 20, 2010 (75 FR 20606); revised
December 5, 2016 (81 FR 87565) and
August 10, 2017 (82 FR 37459)
(extending compliance dates)). For
further assistance, FDA is providing a
technical guide, embedded hints, and a
web tutorial on the electronic portal.
FDA issued a final rule to deem
products meeting the statutory
definition of ‘‘tobacco product’’ to be
subject to the FD&C Act on May 10,
2016 (81 FR 28973), which became
effective on August 8, 2016. The FD&C
Act provides FDA authority to regulate
cigarettes, cigarette tobacco, roll-yourown tobacco (RYO), smokeless tobacco,
and any other tobacco products that the
Agency by regulation deems to be
subject to the law. This final rule
extends the Agency’s ‘‘tobacco product’’
authorities to all other categories of
products that meet the statutory
definition of ‘‘tobacco product’’ in the
FD&C Act, except accessories of such
deemed tobacco products.
For tobacco products subject to the
deeming rule, FDA understands
‘‘current or future tobacco products’’ to
refer to products commercially
distributed on or after August 8, 2016,
or products in any stage of research or
development at any time after August 8,
2016, including experimental products
and developmental products intended
for introduction into the market for
consumer use. For cigarettes, cigarette
tobacco, RYO, and smokeless tobacco,
FDA understands ‘‘current or future
tobacco products’’ to refer to products
commercially distributed on or after
E:\FR\FM\23AUN1.SGM
23AUN1
42666
Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices
June 23, 2009, or products in any stage
of research or development at any time
after June 23, 2009, including
experimental products and
developmental products intended for
introduction into the market for
consumer use.
All manufacturers and importers of
tobacco products are now subject to the
FD&C Act and are required to comply
with section 904(a)(4), which requires
immediate and ongoing submission of
health documents developed after June
22, 2009 (the date of enactment of the
Tobacco Control Act). However, FDA
generally does not intend to enforce the
requirement at this time with respect to
all such health documents relating to
the deemed tobacco products, so long as
a specified set of documents, those
developed between June 23, 2009, and
December 31, 2009, were submitted by
February 8, 2017, or in the case of smallscale deemed tobacco product
manufacturers (small-scale
manufacturers), by November 8, 2017
(81 FR 28974 at 29008–09).
Additionally, FDA extended the
compliance deadlines by an additional
6 months for small-scale manufacturers
in the areas impacted by recent natural
disasters to May 8, 2018. Thereafter,
FDA’s compliance plan requests
deemed manufacturers provide tobacco
health document submissions from the
specified period, at least 90 days prior
to the delivery for introduction into
interstate commerce of tobacco products
to which the health documents relate.
Manufacturers or importers of cigarettes,
cigarette tobacco, RYO, or smokeless
tobacco products must provide all
health documents developed between
June 23, 2009, and December 31, 2009,
at least 90 days prior to the delivery for
introduction of tobacco products into
interstate commerce. FDA estimates the
burden of this collection of information
as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
Tobacco Health Document Submissions and Form FDA
3743 ..................................................................................
10
3.2
32
50
1,600
daltland on DSKBBV9HB2PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The number of documents received
each year since the original collection
period has fallen to less than 5 percent
of what was received in the original
collection period. FDA expects this is
because documents created within the
specified period should have already
been submitted. The Agency bases this
estimate on the total number of tobacco
firms it is aware of and its experience
with document production and the
number of additional documents that
have been reported each year since the
original estimate of the reporting
burden.
FDA estimates that a tobacco health
document submission for cigars, pipe
and waterpipe tobacco, electronic
nicotine delivery systems (ENDS), and
other tobacco products as required by
section 904(a)(4) of the FD&C Act, will
take approximately 50 hours per
submission based on the existing
collection that applies to tobacco
products currently subject to the FD&C
Act and FDA experience. To derive the
number of respondents for this
provision, FDA assumes that very few
manufacturers or importers of deemed
tobacco products, or agents thereof,
would have health documents to
submit. In addition to the existing 4
respondents, the Agency estimates that
approximately 6 submissions (2 for cigar
manufacturers, 1 for pipe and waterpipe
tobacco manufacturers, 1 for other
tobacco product manufacturers, 1 for
tobacco importers, and 1 for importers
of ENDS who are considered
manufacturers) will be submitted on an
VerDate Sep<11>2014
19:43 Aug 22, 2018
Jkt 244001
annual basis for a total of 10
respondents. FDA estimates the total
annual reporting burden to be 1,600
hours.
Based on a review of the information
collection of our current OMB approval,
we have made no adjustments to our
burden estimate.
Dated: August 17, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–18212 Filed 8–22–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–2776]
Evaluating Inclusion and Exclusion
Criteria in Clinical Trials; Workshop
Report; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or the Agency is
announcing the availability of a
summary report of a public workshop
that was held on April 16, 2018, entitled
‘‘Evaluating Inclusion and Exclusion
Criteria in Clinical Trials.’’ The FDA
Reauthorization Act of 2017 (FDARA)
requires that the Agency convene a
public workshop to discuss clinical trial
eligibility criteria to inform a guidance
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
on this subject and to publish a report
summarizing the topics discussed
within 90 days of the public workshop.
This summary report fulfills FDA’s
mandate under FDARA.
ADDRESSES: For persons without
internet access, copies of the summary
report can be requested from the
Division of Drug Information, Food and
Drug Administration, by mail: 10001
New Hampshire Ave, Silver Spring, MD
20993–0002, or toll free telephone: 855–
543–3784.
FOR FURTHER INFORMATION CONTACT:
Dianne Paraoan, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg 51, Rm. 3326,
Silver Spring, MD 20993, 301–796–
2500, Dianne.Paraoan@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 610 of FDARA requires that
FDA convene a public workshop to
discuss clinical trial eligibility criteria
to inform a guidance on this subject and
to publish a report summarizing the
topics discussed within 90 days of the
public workshop (Pub. L. 115–52). On
April 16, 2018, FDA convened the
public workshop required by FDARA
entitled ‘‘Evaluating Inclusion and
Exclusion Criteria in Clinical Trials.’’
This notice announces the availability
of the report required by FDARA that
summarizes the major points explored
with stakeholders during the public
workshop. The report is intended only
as a summary of the workshop
E:\FR\FM\23AUN1.SGM
23AUN1
Agencies
[Federal Register Volume 83, Number 164 (Thursday, August 23, 2018)]
[Notices]
[Pages 42664-42666]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-18212]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0377]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Tobacco Health Document Submission
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on Tobacco Health Document Submissions.
DATES: Submit either electronic or written comments on the collection
of information by October 22, 2018.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before October 22, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of October 22, 2018. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-0377 for ``Tobacco Health Document Submission.'' Received
comments, those filed in a timely manner (see ADDRESSES), will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
[[Page 42665]]
or requirements that members of the public submit reports, keep
records, or provide information to a third party. Section 3506(c)(2)(A)
of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to
provide a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
of an existing collection of information, before submitting the
collection to OMB for approval. To comply with this requirement, FDA is
publishing notice of the proposed collection of information set forth
in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Tobacco Health Document Submission
OMB Control Number 0910-0654--Extension
On June 22, 2009, the President signed the Family Smoking
Prevention and Tobacco Control Act (Tobacco Control Act) (Pub. L. 111-
31) into law. The Tobacco Control Act amended the Federal Food, Drug,
and Cosmetic Act (FD&C Act) by adding, among other things, a new
chapter granting FDA important authority to regulate the manufacture,
marketing, and distribution of tobacco products to protect the public
health generally and to reduce tobacco use by minors. Additionally,
section 101 of the Tobacco Control Act amended the FD&C Act by adding,
among other things, new section 904(a)(4) (21 U.S.C. 387d(a)(4)).
Section 904(a)(4) of the FD&C Act requires each tobacco product
manufacturer or importer, or agent thereof, to submit all documents
developed after June 22, 2009, ``that relate to health, toxicological,
behavioral, or physiologic effects of current or future tobacco
products, their constituents (including smoke constituents),
ingredients, components, and additives'' (herein referred to as
``tobacco health documents'').
FDA announced the availability of a guidance on this collection in
the Federal Register of April 4, 2010 (75 FR 20606) (revised December
5, 2016 (81 FR 87565) and August 10, 2017 (82 FR 37459) (extending
compliance dates)), and requested health documents that were created
during the period of June 23, 2009, through December 31, 2009 based on
the statutory requirements. The guidance stated that information
required under section 904(a)(4) of the FD&C Act must be submitted to
FDA beginning December 22, 2009. However, FDA also explained that it
did not intend to enforce the December 22, 2009, deadline provided that
the documents were submitted by April 30, 2010, for all health
documents developed between June 23, 2009 and December 31, 2009.
Further, FDA stated it would publish a revised guidance specifying the
timing of subsequent reporting.
FDA has been collecting the information submitted pursuant to
section 904(a)(4) of the FD&C Act through a facilitative electronic
form and through a paper form (Form FDA 3743) for those individuals who
choose not to use the electronic method. On both forms, FDA is
requesting the following information from firms that have not already
reported or still have documents to report:
Submitter identification
Submitter type, company name, address, country, company
headquarters Dun and Bradstreet D-U-N-S number, and FDA assigned
Facility Establishment Identifier (FEI) number
Submitter point of contact
Contact name, title, position title, email, telephone, and fax
Submission format and contents (as applicable)
Electronic documents: Media type, media quantity, size of
submission, quantity of documents, file type, and file software
Paper documents: Quantity of documents, quantity of volumes,
and quantity of boxes
Whether or not a submission is being provided
Confirmation statement
Identification and signature of submitter including name,
company name, address, position title, email, telephone, and fax
Document categorization (as applicable): Relationship of the
document or set of documents to the following:
[cir] Health, behavioral, toxicological, or physiological effects
[cir] Uniquely identified current or future tobacco product(s)
[cir] Category of current or future tobacco product(s)
[cir] Specific ingredient(s), constituent(s), component(s), or
additive(s)
[cir] Class of ingredient(s), constituent(s), component(s), or
additive(s)
Document readability and accessibility: Keywords; glossary
or explanation of any abbreviations, jargon, or internal (e.g., code)
names; special instructions for loading or compiling submission.
Document metadata: Date document was created, document
author(s), document recipient(s), document custodian, document title or
identification number, beginning and ending Bates numbers, Bates number
ranges for documents attached to a submitted email, document type, and
whether the document is present in the University of California San
Francisco's Truth Tobacco Documents database.
In addition to the electronic and paper forms, FDA issued guidance
documents intended to assist persons making tobacco health document
submissions (draft guidance: December 28, 2009 (74 FR 68629); final
guidance: April 20, 2010 (75 FR 20606); revised December 5, 2016 (81 FR
87565) and August 10, 2017 (82 FR 37459) (extending compliance dates)).
For further assistance, FDA is providing a technical guide, embedded
hints, and a web tutorial on the electronic portal.
FDA issued a final rule to deem products meeting the statutory
definition of ``tobacco product'' to be subject to the FD&C Act on May
10, 2016 (81 FR 28973), which became effective on August 8, 2016. The
FD&C Act provides FDA authority to regulate cigarettes, cigarette
tobacco, roll-your-own tobacco (RYO), smokeless tobacco, and any other
tobacco products that the Agency by regulation deems to be subject to
the law. This final rule extends the Agency's ``tobacco product''
authorities to all other categories of products that meet the statutory
definition of ``tobacco product'' in the FD&C Act, except accessories
of such deemed tobacco products.
For tobacco products subject to the deeming rule, FDA understands
``current or future tobacco products'' to refer to products
commercially distributed on or after August 8, 2016, or products in any
stage of research or development at any time after August 8, 2016,
including experimental products and developmental products intended for
introduction into the market for consumer use. For cigarettes,
cigarette tobacco, RYO, and smokeless tobacco, FDA understands
``current or future tobacco products'' to refer to products
commercially distributed on or after
[[Page 42666]]
June 23, 2009, or products in any stage of research or development at
any time after June 23, 2009, including experimental products and
developmental products intended for introduction into the market for
consumer use.
All manufacturers and importers of tobacco products are now subject
to the FD&C Act and are required to comply with section 904(a)(4),
which requires immediate and ongoing submission of health documents
developed after June 22, 2009 (the date of enactment of the Tobacco
Control Act). However, FDA generally does not intend to enforce the
requirement at this time with respect to all such health documents
relating to the deemed tobacco products, so long as a specified set of
documents, those developed between June 23, 2009, and December 31,
2009, were submitted by February 8, 2017, or in the case of small-scale
deemed tobacco product manufacturers (small-scale manufacturers), by
November 8, 2017 (81 FR 28974 at 29008-09). Additionally, FDA extended
the compliance deadlines by an additional 6 months for small-scale
manufacturers in the areas impacted by recent natural disasters to May
8, 2018. Thereafter, FDA's compliance plan requests deemed
manufacturers provide tobacco health document submissions from the
specified period, at least 90 days prior to the delivery for
introduction into interstate commerce of tobacco products to which the
health documents relate. Manufacturers or importers of cigarettes,
cigarette tobacco, RYO, or smokeless tobacco products must provide all
health documents developed between June 23, 2009, and December 31,
2009, at least 90 days prior to the delivery for introduction of
tobacco products into interstate commerce. FDA estimates the burden of
this collection of information as follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Tobacco Health Document Submissions and Form FDA 3743.............. 10 3.2 32 50 1,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
The number of documents received each year since the original
collection period has fallen to less than 5 percent of what was
received in the original collection period. FDA expects this is because
documents created within the specified period should have already been
submitted. The Agency bases this estimate on the total number of
tobacco firms it is aware of and its experience with document
production and the number of additional documents that have been
reported each year since the original estimate of the reporting burden.
FDA estimates that a tobacco health document submission for cigars,
pipe and waterpipe tobacco, electronic nicotine delivery systems
(ENDS), and other tobacco products as required by section 904(a)(4) of
the FD&C Act, will take approximately 50 hours per submission based on
the existing collection that applies to tobacco products currently
subject to the FD&C Act and FDA experience. To derive the number of
respondents for this provision, FDA assumes that very few manufacturers
or importers of deemed tobacco products, or agents thereof, would have
health documents to submit. In addition to the existing 4 respondents,
the Agency estimates that approximately 6 submissions (2 for cigar
manufacturers, 1 for pipe and waterpipe tobacco manufacturers, 1 for
other tobacco product manufacturers, 1 for tobacco importers, and 1 for
importers of ENDS who are considered manufacturers) will be submitted
on an annual basis for a total of 10 respondents. FDA estimates the
total annual reporting burden to be 1,600 hours.
Based on a review of the information collection of our current OMB
approval, we have made no adjustments to our burden estimate.
Dated: August 17, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-18212 Filed 8-22-18; 8:45 am]
BILLING CODE 4164-01-P